top of page

India's Serum Institute to Make Millions of Potential Coronavirus Vaccine Doses

  • Apr 30, 2020
  • 1 min read

NEW DELHI — The Serum Institute of India said on Tuesday it plans this year to produce up to 60 million doses of a potential vaccine against the new coronavirus that is under clinical trial in Britain.


Serum, the world’s largest maker of vaccines by volume, is mass-producing the vaccine candidate developed by the University of Oxford, which started testing it on humans last week, and is a leader in the global race to develop an antidote to the novel coronavirus.

Some 3.05 million people have been reported to be infected globally and 211,376 have died from COVID-19, the respiratory disease caused by the coronavirus, according to a Reuters tally.

While the Oxford vaccine, called "ChAdOx1 nCoV-19", is yet to be proven to work against COVID-19, Serum decided to start manufacturing it as it had shown success in animal trials and had progressed to tests on humans, Serum Chief Executive Adar Poonawalla said.

ByReuters

April 28, 2020

 
 
 

Commentaires


Mindcept-Logo.png

© MINDCEPT CONSULTING

  • LinkedIn

DISCLAIMER: The information contained in this website is offered for illustration purposes only and is general information. We make no representations or warranties of any kind (express or implied) with respect to the information, products, services, statements, figures, calculations, plans, images, logos, related graphics and are purely indicative in nature only. Whilst all reasonable care has been taking in providing all information, however, We or / and our related companies or/ and our representatives, consultants or / and our agents accept no responsibility for its completeness, accuracy, reliability, suitability or availability of any information contained herein for any action taken in reliance thereon by any party. Any reliance on information as contained in this website does not constitute an offer, inducement, representation, warranty or contract and may be relied upon at one’s risk and consequences.

bottom of page